{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:39:35Z","timestamp":1784907575507,"version":"3.55.0"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Prostate cancer (PCa) is the second most commonly diagnosed cancer worldwide and the 5th leading cause of death from cancer for men in Taiwan. The incidence of synchronous metastatic PCa in Taiwan is higher than U.S. and Europe. We aim to present the latest life expectancy (LE), loss of LE, and lifetime cost associated with PCa in Taiwan. The PCa data are based on Taiwan Cancer Registry and National Health Insurance Database. Total 30,207 new cases of PCa were recorded during 2008-2019 nationwide. LE, estimated loss of LE and lifetime cost were stratified by age, cancer stage, Gleason score, grade group and serum PSA level at diagnosis. We compared LE and healthcare cost outcomes between synchronous metastatic PCa patients in 3 age groups. Among the 30,207 new cases, the low to intermediate risk groups, high-risk groups, and regional and metastatic PCa accounted for 54.1%, 13.2%, and 32.6% of cases, respectively. A considerable proportion of synchronous metastatic PCa was noted in Taiwan when compared with the U.S. For synchronous metastatic PCa, the highest LE is 9.22 years for ages 20-64 years, followed by ages 65-74 (8.29 years) and ages 75-89 years (4.58 years). The loss of LE in the three age groups is 13.63, 6.75, and 3.87 years, respectively. The healthcare cost of synchronous metastatic PCa in all age groups is higher than the average cost for PCa patients in Taiwan. This study provides real-world evidence to support health care policy-making and clinical decisions regarding PCa. Due to the high proportion of synchronous metastatic PCa in Taiwan, the findings of this analysis emphasize the importance of early detection of PCa, which can save LE and decrease the total cost burden on the healthcare system.<\/jats:p>","DOI":"10.1371\/journal.pone.0310613","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T13:41:39Z","timestamp":1744119699000},"page":"e0310613","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive analysis of prostate cancer life expectancy, loss of life expectancy, and healthcare expenditures: Taiwan national cohort study spanning 2008 to 2019"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6016-7816","authenticated-orcid":true,"given":"Pin-Chun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6080-7231","authenticated-orcid":true,"given":"Yen-Chuan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yu","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Che","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ming","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"12","key":"pone.0310613.ref001","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the Global Burden of Disease Study","volume":"5","author":"Global Burden of Disease Cancer Collaboration","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"pone.0310613.ref002","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"R Siegel","year":"2020","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"pone.0310613.ref003","author":"Statistics of cause of death ministry of health and warfare","year":"2019"},{"issue":"6","key":"pone.0310613.ref004","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/iju.13593","article-title":"Epidemiology of prostate cancer in Asian countries","volume":"25","author":"T Kimura","year":"2018","journal-title":"Int J Urol"},{"issue":"1","key":"pone.0310613.ref005","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.2217\/fon-2019-0639","article-title":"Economic burden of illness associated with localized prostate cancer in the United States","volume":"16","author":"G Gustavsen","year":"2020","journal-title":"Future Oncol"},{"issue":"1","key":"pone.0310613.ref006","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12894-019-0448-6","article-title":"Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada","volume":"19","author":"J Smith-Palmer","year":"2019","journal-title":"BMC Urol"},{"issue":"11","key":"pone.0310613.ref007","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/pros.24360","article-title":"Current and projected number of years of life lost due to prostate cancer: A global study","volume":"82","author":"D Withrow","year":"2022","journal-title":"Prostate"},{"issue":"13","key":"pone.0310613.ref008","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/(SICI)1097-0258(19990715)18:13<1627::AID-SIM159>3.0.CO;2-D","article-title":"Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies","volume":"18","author":"JS Hwang","year":"1999","journal-title":"Stat Med"},{"issue":"12","key":"pone.0310613.ref009","first-page":"e332","article-title":"Estimating lifetime medical costs from censored claims data","volume":"26","author":"J-S Hwang","year":"2017","journal-title":"Health Econ"},{"issue":"3","key":"pone.0310613.ref010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jjco\/hyu211","article-title":"Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review","volume":"45","author":"C-J Chiang","year":"2015","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"pone.0310613.ref011","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/art.41597","article-title":"Lifetime Risks, Life Expectancy, and Health Care Expenditures for Rheumatoid Arthritis: A Nationwide Cohort Followed Up From 2003 to 2016","volume":"73","author":"Y-M Chiu","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"pone.0310613.ref012","first-page":"677","article-title":"Life expectancy, expected years of life lost and survival of hemodialysis and peritoneal dialysis patients","volume":"23","author":"T-W Kao","year":"2010","journal-title":"J Nephrol"},{"issue":"6","key":"pone.0310613.ref013","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3747\/pdi.2012.00081","article-title":"Lifetime costs for peritoneal dialysis and hemodialysis in patients in Taiwan","volume":"33","author":"T-W Kao","year":"2013","journal-title":"Perit Dial Int"},{"issue":"1\u20133","key":"pone.0310613.ref014","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2016.01.033","article-title":"Estimation of life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in Taiwan","volume":"171","author":"CH L\u00eang","year":"2016","journal-title":"Schizophr Res"},{"key":"pone.0310613.ref015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2147\/CLEP.S155601","article-title":"Lifetime risks, loss of life expectancy, and health care expenditures for 19 types of cancer in Taiwan","volume":"10","author":"T-Y Wu","year":"2018","journal-title":"Clin Epidemiol"},{"issue":"1","key":"pone.0310613.ref016","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1590\/S1677-55382008000100007","article-title":"Prostate specific antigen levels following transurethral resection of the prostate","volume":"34","author":"RC Fonseca","year":"2008","journal-title":"Int Braz J Urol"},{"issue":"41","key":"pone.0310613.ref017","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017","volume":"69","author":"D Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0310613.ref018","unstructured":"Taiwan National Health Insurance. Statistical table of medical expenditures for the cancers. 2019."},{"issue":"17","key":"pone.0310613.ref019","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-specific antigen screening and 15-year prostate cancer mortality: A secondary analysis of the CAP randomized clinical trial","volume":"331","author":"R Martin","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"pone.0310613.ref020","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/jamainternmed.2023.3798","article-title":"Estimated Lifetime Gained With Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials","volume":"183","author":"M Bretthauer","year":"2023","journal-title":"JAMA Intern Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T13:42:00Z","timestamp":1744119720000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310613"}},"subtitle":[],"editor":[{"given":"Po-Fan","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0310613","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.05.24313122","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]}}}